<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368250</url>
  </required_header>
  <id_info>
    <org_study_id>056/11</org_study_id>
    <nct_id>NCT01368250</nct_id>
  </id_info>
  <brief_title>SwissTAVI Registry</brief_title>
  <official_title>SwissTAVI Registry: Prospective, National, Multi-Center Registry of Patients Undergoing Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective multi-center, observational national registry in Switzerland&#xD;
      is to obtain clinical baseline, procedural and follow-up data of all patients treated with&#xD;
      TAVI in Switzerland and to assess short, mid- and long-term clinical outcome data of the CE&#xD;
      approved devices. All centers in Switzerland implanting the CE approved devices for TAVI will&#xD;
      be invited to include patients in the registry. Each site will collect baseline and&#xD;
      procedural data as well as clinical outcome data up to five years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present registry aims to assess the safety and efficacy of TAVI with CE approved devices&#xD;
      at Swiss cardiovascular centers. The Swiss Working group of Interventional Cardiology and&#xD;
      Acute Coronary Syndrome decided to establish a nationwide registry in collaboration with the&#xD;
      Swiss Society of Cardiac Surgery in order to assess the procedural and clinical outcome of&#xD;
      TAVI patients. This prospective registry will help to identify candidates for TAVI, will&#xD;
      report on peri-procedural outcome and on long-term efficacy of the devices. Last but not&#xD;
      least it is a tool to increase quality of treatment of this high-risk patient population.&#xD;
&#xD;
      Methods&#xD;
&#xD;
      This is a prospective multi-center, observational registry performed in Switzerland. All&#xD;
      centers in Switzerland implanting the CE approved devices for TAVI will be invited to&#xD;
      consecutively include patients in the registry. Each center will sign an agreement that all&#xD;
      patients will be included in the registry. Each site will collect baseline and procedural&#xD;
      data as well as clinical outcome data up to 15 years after TAVI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>combined early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)</measure>
    <time_frame>1 year</time_frame>
    <description>Composed by:&#xD;
death&#xD;
stroke&#xD;
aortic valve re-intervention&#xD;
structural valve deterioration&#xD;
myocardial Infarction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>combined early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)</measure>
    <time_frame>30days</time_frame>
    <description>Composed by:&#xD;
death&#xD;
stroke&#xD;
aortic valve re-intervention&#xD;
myocardial Infarction&#xD;
kidney injury&#xD;
access related complications&#xD;
pacemaker requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combined safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)</measure>
    <time_frame>5 years</time_frame>
    <description>Composed by:&#xD;
death&#xD;
stroke&#xD;
aortic valve re-intervention&#xD;
structural valve deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combined safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)</measure>
    <time_frame>10 years , 15 years</time_frame>
    <description>Composed by:&#xD;
death&#xD;
stroke&#xD;
aortic valve re-intervention&#xD;
structural valve deterioration</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Aortic Valve Disease Mixed</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with native aortic stenosis undergoing TAVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with native aortic regurgitation undergoing TAVI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>Minimal Invasive Implantation of a biological prosthesis in Aortic Position</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aortic valve disease or degenerated aortic bioprosthesis scheduled to undergo&#xD;
        transcatheter aortic valve implantation (TAVI) using commercially available devices with CE&#xD;
        approval are eligible for enrollment in the registry. The TAVI procedure can be performed&#xD;
        using all available access routes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Native aortic valve stenosis&#xD;
&#xD;
          -  Native aortic valve regurgitation&#xD;
&#xD;
          -  Degenerated aortic bioprosthesis requiring treatment&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients refuses informed consent to participate in the registry&#xD;
&#xD;
          -  Contraindication for TAVI&#xD;
&#xD;
          -  High probability of non-adherence to the follow up - requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Stortecky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bern University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Stortecky, MD</last_name>
    <phone>0041 31 632 83 52</phone>
    <email>stefan.stortecky@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Windecker, MD</last_name>
    <phone>0041 31 632 83 52</phone>
    <email>stephan.windecker@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Stortecky, MD</last_name>
      <phone>0041 31 632 21 11</phone>
      <email>stefan.stortecky@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Stortecky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Windecker, MD</last_name>
      <phone>0041 31 632 21 11</phone>
      <email>stephan.windecker@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve</keyword>
  <keyword>Heart valve</keyword>
  <keyword>VARC</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>Minimal-invasive</keyword>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

